<?xml version="1.0" encoding="UTF-8"?>
<p id="Par50">The outbreak of COVID-19 has drastically changed the diagnosis, treatment and follow-up of patients with chronic HCV at a time when general practitioners are actively engaged in the early detection of SARS-CoV-2 infection among their patients. Telemedicine has certainly continued to allow specialists to prescribe DAAs as well as monitor patients under treatment, whereas screening may still be implemented. As pointed out by the Alliance Against Hepatitis Association (Alleanza contro l'Epatite)Â [
 <xref ref-type="bibr" rid="CR12">12</xref>], joint HCV/SARS-CoV-2 screening could accelerate the path towards the elimination of HCV and the achievement of the objectives indicated by the WHO for 2030.
</p>
